Dr. Emi H. Caywood

About Emi H. Caywood

Education:

• Earned an MD from the University of Medicine and Dentistry of New Jersey in 2002.
• Completed a Residency in Pediatrics at Georgetown University Hospital in 2005.
• Finished a Fellowship in Pediatric Hematology/Oncology at Johns Hopkins University in 2009.

Experience:

• Board Certified in Pediatrics and Pediatric Hematology-Oncology.
• Recognized as a Top Doctor by Delaware Today magazine in 2014 and a Hyundai Hope on Wheels Grant Scholar in 2008.
• Specializes in treating children with cancers and blood disorders at Nemours Children's Health, Philadelphia, PA.

Area of expertise

Affiliated Hospitals

Alfred I DuPont Hospital For Children

Nemours Children's Clinic-Jacksonville

Clinical Trials Emi H. Caywood is currently running

Non-TBI Conditioning

for HCT in Acute Lymphoblastic Leukemia

This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hematopoietic cell transplant (HCT). Patients diagnosed with B-ALL who are candidates for HCT will be screened by NGS-MRD on a test of bone marrow done before the HCT. Subjects who are pre-HCT NGS-MRD negative will be eligible to receive a non-TBI conditioning regimen as part of the treatment cohort of the study. Subjects who are pre-HCT NGS-MRD positive will be treated as per treating center standard and will be followed in an observational cohort (HCT center standard of care).

Recruiting1 award Phase 2

IST + BMT

for Aplastic Anemia

Severe Aplastic Anemia (SAA) is a rare condition in which the body stops producing enough new blood cells. SAA can be cured with immune suppressive therapy or a bone marrow transplant. Regular treatment for patients with aplastic anemia who have a matched sibling (brother or sister), or family donor is a bone marrow transplant. Patients without a matched family donor normally are treated with immune suppressive therapy (IST). Match unrelated donor (URD) bone marrow transplant (BMT) is used as a secondary treatment in patients who did not get better with IST, had their disease come back, or a new worse disease replaced it (like leukemia). This trial will compare time from randomization to failure of treatment or death from any cause of IST versus URD BMT when used as initial therapy to treat SAA. The trial will also assess whether health-related quality of life and early markers of fertility differ between those randomized to URD BMT or IST, as well as assess the presence of marrow failure-related genes and presence of gene mutations associated with MDS or leukemia and the change in gene signatures after treatment in both study arms. This study treatment does not include any investigational drugs. The medicines and procedures in this study are standard for treatment of SAA.

Recruiting2 awards Phase 3

More about Emi H. Caywood

Other Doctors you might be interested in

Frequently asked questions